{"product_id":"vascepa-icosapent-ethyl","title":"Vascepa (Icosapent Ethyl)","description":"\u003ch3 data-start=\"333\" data-end=\"363\"\u003eWhat is Icosapent Ethyl?\u003c\/h3\u003e\r\n\u003cp data-start=\"364\" data-end=\"755\"\u003eIcosapent Ethyl is a highly purified ethyl ester of eicosapentaenoic acid (EPA), an omega‑3 fatty acid. It is prescribed as an adjunct to diet to lower elevated triglyceride levels and reduce the risk of major cardiovascular events in high‑risk patients. It is available under its brand name \u003cstrong data-start=\"656\" data-end=\"705\"\u003e\u003ca target=\"_new\" rel=\"noopener\" data-start=\"658\" data-end=\"703\"\u003eVascepa\u003c\/a\u003e\u003c\/strong\u003e and is also known generically as Icosapent Ethyl.\u003c\/p\u003e\r\n\u003cp data-start=\"757\" data-end=\"940\"\u003e\u003cem data-start=\"757\" data-end=\"940\"\u003eReference: \u003ca target=\"_new\" rel=\"noopener\" data-start=\"769\" data-end=\"865\"\u003eFDA Vascepa Label\u003c\/a\u003e, \u003ca target=\"_new\" rel=\"noopener\" data-start=\"867\" data-end=\"939\"\u003eDrugs.com: Icosapent Ethyl\u003c\/a\u003e\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"942\" data-end=\"945\"\u003e\r\n\u003ch3 data-start=\"947\" data-end=\"1006\"\u003eWhat are the other popular names for Icosapent Ethyl?\u003c\/h3\u003e\r\n\u003cp data-start=\"1007\" data-end=\"1151\"\u003eThe most recognized brand name is \u003cstrong data-start=\"1041\" data-end=\"1052\"\u003eVascepa\u003c\/strong\u003e. In clinical practice and literature, it is also referred to by its generic name, Icosapent Ethyl.\u003c\/p\u003e\r\n\u003cp data-start=\"1153\" data-end=\"1238\"\u003e\u003cem data-start=\"1153\" data-end=\"1238\"\u003eReference: \u003ca target=\"_new\" rel=\"noopener\" data-start=\"1165\" data-end=\"1237\"\u003eDrugs.com: Icosapent Ethyl\u003c\/a\u003e\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"1240\" data-end=\"1243\"\u003e\r\n\u003ch3 data-start=\"1245\" data-end=\"1302\"\u003eWhat is the drug classification of Icosapent Ethyl?\u003c\/h3\u003e\r\n\u003cp data-start=\"1303\" data-end=\"1522\"\u003eIcosapent Ethyl is classified as an \u003cstrong data-start=\"1339\" data-end=\"1372\"\u003eomega‑3 fatty acid derivative\u003c\/strong\u003e. More specifically, it is an ethyl ester of EPA, and it is considered a prescription medical food for reducing triglycerides and cardiovascular risk.\u003c\/p\u003e\r\n\u003cp data-start=\"1524\" data-end=\"1633\"\u003e\u003cem data-start=\"1524\" data-end=\"1633\"\u003eReference: \u003ca target=\"_new\" rel=\"noopener\" data-start=\"1536\" data-end=\"1632\"\u003eFDA Vascepa Label\u003c\/a\u003e\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"1635\" data-end=\"1638\"\u003e\r\n\u003ch3 data-start=\"1640\" data-end=\"1692\"\u003eWhat is the mode of action of Icosapent Ethyl?\u003c\/h3\u003e\r\n\u003cp data-start=\"1693\" data-end=\"1832\"\u003eOnce ingested, Icosapent Ethyl is hydrolyzed to release EPA, which is then incorporated into cell membranes. Its mode of action includes:\u003c\/p\u003e\r\n\u003cul data-start=\"1833\" data-end=\"2271\"\u003e\r\n\u003cli data-start=\"1833\" data-end=\"1993\"\u003e\n\u003cstrong data-start=\"1835\" data-end=\"1875\"\u003eReduction of Hepatic VLDL Production\u003c\/strong\u003e: EPA decreases the liver’s production of very‑low‑density lipoprotein (VLDL), thereby reducing triglyceride levels.\u003c\/li\u003e\r\n\u003cli data-start=\"1994\" data-end=\"2138\"\u003e\n\u003cstrong data-start=\"1996\" data-end=\"2025\"\u003eAnti‑Inflammatory Effects\u003c\/strong\u003e: EPA has anti‑inflammatory properties that help stabilize atherosclerotic plaques and reduce oxidative stress.\u003c\/li\u003e\r\n\u003cli data-start=\"2139\" data-end=\"2271\"\u003e\n\u003cstrong data-start=\"2141\" data-end=\"2180\"\u003eImprovement in Endothelial Function\u003c\/strong\u003e: Enhancing the health of blood vessels, contributing to overall cardiovascular protection.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"2273\" data-end=\"2363\"\u003e\u003cem data-start=\"2273\" data-end=\"2363\"\u003eReference: \u003ca target=\"_new\" rel=\"noopener\" data-start=\"2285\" data-end=\"2362\"\u003eREDUCE‑IT Trial – NEJM\u003c\/a\u003e\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"2365\" data-end=\"2368\"\u003e\r\n\u003ch3 data-start=\"2370\" data-end=\"2422\"\u003eWhat is the clinical usage of Icosapent Ethyl?\u003c\/h3\u003e\r\n\u003cp data-start=\"2423\" data-end=\"2494\"\u003eIcosapent Ethyl is used as an adjunct to diet in adult patients with:\u003c\/p\u003e\r\n\u003cul data-start=\"2495\" data-end=\"2750\"\u003e\r\n\u003cli data-start=\"2495\" data-end=\"2609\"\u003e\n\u003cstrong data-start=\"2497\" data-end=\"2521\"\u003eHypertriglyceridemia\u003c\/strong\u003e: Particularly in patients with triglyceride levels ≥150 mg\/dL despite statin therapy.\u003c\/li\u003e\r\n\u003cli data-start=\"2610\" data-end=\"2750\"\u003e\n\u003cstrong data-start=\"2612\" data-end=\"2645\"\u003eCardiovascular Risk Reduction\u003c\/strong\u003e: It is indicated to reduce the risk of major adverse cardiovascular events (MACE) in high‑risk patients.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"2752\" data-end=\"2940\"\u003e\u003cem data-start=\"2752\" data-end=\"2940\"\u003eReference: \u003ca target=\"_new\" rel=\"noopener\" data-start=\"2764\" data-end=\"2841\"\u003eREDUCE‑IT Trial – NEJM\u003c\/a\u003e, \u003ca target=\"_new\" rel=\"noopener\" data-start=\"2843\" data-end=\"2939\"\u003eFDA Vascepa Label\u003c\/a\u003e\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"2942\" data-end=\"2945\"\u003e\r\n\u003ch3 data-start=\"2947\" data-end=\"3027\"\u003eWhat is the recommended dosage and usage instructions for Icosapent Ethyl?\u003c\/h3\u003e\r\n\u003cul data-start=\"3028\" data-end=\"3376\"\u003e\r\n\u003cli data-start=\"3028\" data-end=\"3127\"\u003e\n\u003cstrong data-start=\"3030\" data-end=\"3040\"\u003eDosage\u003c\/strong\u003e: The typical recommended dose is \u003cstrong data-start=\"3074\" data-end=\"3097\"\u003e2 grams twice daily\u003c\/strong\u003e (totaling 4 grams per day).\u003c\/li\u003e\r\n\u003cli data-start=\"3128\" data-end=\"3267\"\u003e\n\u003cstrong data-start=\"3130\" data-end=\"3148\"\u003eAdministration\u003c\/strong\u003e: Icosapent Ethyl is administered orally as a soft gelatin capsule and should be taken with food to enhance absorption.\u003c\/li\u003e\r\n\u003cli data-start=\"3268\" data-end=\"3376\"\u003e\n\u003cstrong data-start=\"3270\" data-end=\"3279\"\u003eUsage\u003c\/strong\u003e: It is prescribed in addition to a maximally tolerated statin regimen and dietary modifications.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"3378\" data-end=\"3487\"\u003e\u003cem data-start=\"3378\" data-end=\"3487\"\u003eReference: \u003ca target=\"_new\" rel=\"noopener\" data-start=\"3390\" data-end=\"3486\"\u003eFDA Vascepa Label\u003c\/a\u003e\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"3489\" data-end=\"3492\"\u003e\r\n\u003ch3 data-start=\"3494\" data-end=\"3562\"\u003eWhat prescribing information is important for Icosapent Ethyl?\u003c\/h3\u003e\r\n\u003cul data-start=\"3563\" data-end=\"3929\"\u003e\r\n\u003cli data-start=\"3563\" data-end=\"3642\"\u003e\n\u003cstrong data-start=\"3565\" data-end=\"3588\"\u003ePrescription Status\u003c\/strong\u003e: Icosapent Ethyl is a prescription-only medication.\u003c\/li\u003e\r\n\u003cli data-start=\"3643\" data-end=\"3791\"\u003e\n\u003cstrong data-start=\"3645\" data-end=\"3660\"\u003eIndications\u003c\/strong\u003e: It is indicated for patients with elevated triglycerides and high cardiovascular risk as an adjunct to diet and statin therapy.\u003c\/li\u003e\r\n\u003cli data-start=\"3792\" data-end=\"3929\"\u003e\n\u003cstrong data-start=\"3794\" data-end=\"3808\"\u003eMonitoring\u003c\/strong\u003e: Regular monitoring of lipid profiles, liver enzymes, and potential side effects is recommended by healthcare providers.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"3931\" data-end=\"4040\"\u003e\u003cem data-start=\"3931\" data-end=\"4040\"\u003eReference: \u003ca target=\"_new\" rel=\"noopener\" data-start=\"3943\" data-end=\"4039\"\u003eFDA Vascepa Label\u003c\/a\u003e\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"4042\" data-end=\"4045\"\u003e\r\n\u003ch3 data-start=\"4047\" data-end=\"4129\"\u003eWhat are the safety information, warnings, and cautions for Icosapent Ethyl?\u003c\/h3\u003e\r\n\u003cul data-start=\"4130\" data-end=\"4979\"\u003e\r\n\u003cli data-start=\"4130\" data-end=\"4289\"\u003e\n\u003cstrong data-start=\"4132\" data-end=\"4155\"\u003eCommon Side Effects\u003c\/strong\u003e: These include gastrointestinal symptoms (diarrhea, abdominal pain), musculoskeletal pain, and a small risk of atrial fibrillation.\u003c\/li\u003e\r\n\u003cli data-start=\"4290\" data-end=\"4816\"\u003e\n\u003cstrong data-start=\"4292\" data-end=\"4317\"\u003eWarnings and Cautions\u003c\/strong\u003e:\r\n\u003cul data-start=\"4321\" data-end=\"4816\"\u003e\r\n\u003cli data-start=\"4321\" data-end=\"4450\"\u003e\n\u003cstrong data-start=\"4323\" data-end=\"4340\"\u003eBleeding Risk\u003c\/strong\u003e: There may be an increased risk of bleeding, especially in patients on anticoagulant or antiplatelet therapy.\u003c\/li\u003e\r\n\u003cli data-start=\"4453\" data-end=\"4557\"\u003e\n\u003cstrong data-start=\"4455\" data-end=\"4478\"\u003eAtrial Fibrillation\u003c\/strong\u003e: Monitor for new-onset atrial fibrillation, as noted in some clinical studies.\u003c\/li\u003e\r\n\u003cli data-start=\"4560\" data-end=\"4696\"\u003e\n\u003cstrong data-start=\"4562\" data-end=\"4583\"\u003eDrug Interactions\u003c\/strong\u003e: Caution is advised when used concurrently with other medications that affect lipid metabolism or bleeding risk.\u003c\/li\u003e\r\n\u003cli data-start=\"4699\" data-end=\"4816\"\u003e\n\u003cstrong data-start=\"4701\" data-end=\"4722\"\u003eContraindications\u003c\/strong\u003e: Patients with known hypersensitivity to Icosapent Ethyl or its components should not use it.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"4817\" data-end=\"4979\"\u003e\n\u003cstrong data-start=\"4819\" data-end=\"4834\"\u003ePrecautions\u003c\/strong\u003e: Patients should be advised to report any unusual symptoms such as severe muscle pain, persistent gastrointestinal issues, or signs of bleeding.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"4981\" data-end=\"5182\"\u003e\u003cem data-start=\"4981\" data-end=\"5182\"\u003eReference: \u003ca target=\"_new\" rel=\"noopener\" data-start=\"4993\" data-end=\"5102\"\u003eFDA Vascepa Safety Information\u003c\/a\u003e, \u003ca target=\"_new\" rel=\"noopener\" data-start=\"5104\" data-end=\"5181\"\u003eREDUCE‑IT Trial – NEJM\u003c\/a\u003e\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"5184\" data-end=\"5187\"\u003e\r\n\u003ch3 data-start=\"5189\" data-end=\"5266\"\u003eWhere can I learn more about Icosapent Ethyl and its clinical evidence?\u003c\/h3\u003e\r\n\u003cp data-start=\"5267\" data-end=\"5378\"\u003eFor further details on clinical data, dosage, and safety, healthcare professionals and patients can refer to:\u003c\/p\u003e\r\n\u003cul data-start=\"5379\" data-end=\"5742\"\u003e\r\n\u003cli data-start=\"5379\" data-end=\"5481\"\u003e\u003cstrong data-start=\"5381\" data-end=\"5481\"\u003e\u003ca target=\"_new\" rel=\"noopener\" data-start=\"5383\" data-end=\"5479\"\u003eFDA Vascepa Label\u003c\/a\u003e\u003c\/strong\u003e\u003c\/li\u003e\r\n\u003cli data-start=\"5482\" data-end=\"5577\"\u003e\u003cstrong data-start=\"5484\" data-end=\"5577\"\u003e\u003ca target=\"_new\" rel=\"noopener\" data-start=\"5486\" data-end=\"5575\"\u003eREDUCE‑IT Trial Publication – NEJM\u003c\/a\u003e\u003c\/strong\u003e\u003c\/li\u003e\r\n\u003cli data-start=\"5578\" data-end=\"5656\"\u003e\u003cstrong data-start=\"5580\" data-end=\"5656\"\u003e\u003ca target=\"_new\" rel=\"noopener\" data-start=\"5582\" data-end=\"5654\"\u003eDrugs.com: Icosapent Ethyl\u003c\/a\u003e\u003c\/strong\u003e\u003c\/li\u003e\r\n\u003cli data-start=\"5657\" data-end=\"5742\"\u003e\n\u003cstrong data-start=\"5659\" data-end=\"5705\"\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/\" target=\"_new\" rel=\"noopener\" data-start=\"5661\" data-end=\"5703\"\u003ePubMed\u003c\/a\u003e\u003c\/strong\u003e for additional peer-reviewed studies\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003chr data-start=\"5744\" data-end=\"5747\"\u003e\r\n\u003ch3 data-start=\"5749\" data-end=\"5769\"\u003eFinal Thoughts\u003c\/h3\u003e\r\n\u003cp data-start=\"5770\" data-end=\"6296\"\u003e\u003cstrong data-start=\"5770\" data-end=\"5799\"\u003eIcosapent Ethyl (Vascepa)\u003c\/strong\u003e is a clinically proven omega‑3 fatty acid derivative that plays a crucial role in lowering triglyceride levels and reducing cardiovascular risk in high‑risk patients. With its well‑documented mode of action and robust clinical evidence from the REDUCE‑IT trial, Icosapent Ethyl represents a significant advancement in cardiovascular risk management. As always, it should be used under the guidance of a healthcare professional, with careful monitoring for potential side effects and interactions.\u003c\/p\u003e\r\n\u003cp data-start=\"6298\" data-end=\"6522\"\u003e\u003cem data-start=\"6298\" data-end=\"6522\"\u003eDisclaimer: This information is provided for educational purposes only and should not replace professional medical advice. Always consult with your healthcare provider before initiating or modifying any medication regimen.\u003c\/em\u003e\u003c\/p\u003e","brand":"Magento","offers":[{"title":"1000mg \/ 28","offer_id":49210174406902,"sku":"Vascepa-1000mg-28-1","price":73.5,"currency_code":"USD","in_stock":true},{"title":"500mg \/ 28","offer_id":49210174439670,"sku":"Vascepa-500mg-28-1","price":58.2,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0756\/1855\/0006\/files\/untitled_design_55.png?v=1760863803","url":"https:\/\/chemistway.com\/products\/vascepa-icosapent-ethyl","provider":"Chemistway","version":"1.0","type":"link"}